- Continued acceleration in quarterly revenue growth since Q2
2024, with Q4 2024 reaching nearly €3.0 million, up 81% versus
2023
- Strong full-year performance in the medical equipment
distribution business, generating €2.3 million in revenue
Regulatory News:
IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible
for PEA-PME equity savings plans), a medical technology company
specializing in implants for orthopedic surgery and the
distribution of technological medical equipment, today announces
its full-year 2024 revenue and cash position as of December 31,
2024.
Ludovic Lastennet, IMPLANET’s Chief Executive Officer,
stated: “The strong commercial performance achieved in the second
half of 2024, with 66% growth compared to the same period last
year, underscores the effectiveness of the development model
implemented at the start of 2024. Building on our expertise in
spine surgery and the synergy between our product ranges, the
combination of implant sales with the distribution of high-value
medical equipment has significantly increased our sales across
strategic markets. While the first half of 2024 was impacted by a
slowdown in international activity, we are now reaping the benefits
of our investments in the United States and are more convinced than
ever of the strong growth potential of our solutions in this
region. With the support of our key shareholder, Sanyou Medical, we
intend to sustain this growth momentum by expanding our product
offerings and continuing our innovation strategy.”
Fourth quarter 2024 growth of
+81%
Revenue by Activity (in € thousands
- IFRS Standards1)
2024
2023
Change %
Spine Implants
1,871
1,608
+16%
Medical Equipment (SMTP)
1,110
24
-
Services (MADISON)
1
11
-
Total Revenue for the fourth
quarter
2,982
1,643
+81%
The Spine Implants activity achieved Q4 2024 revenue of €1.87
million, an increase of +16% compared to €1.61 million in Q4
2023.
The medical equipment distribution activity continued its
growth, supported by the ongoing deployment of the Olea ultrasonic
scalpel in France, internationally, and in the U.S. under the
exclusive partnership with elliquence for the spinal endoscopy
market. Revenue from this activity for Q4 2024 was €1.11 million,
compared to €0.02 million in Q4 2023.
Activity in France grew by +8%, with revenue of €1.04 million
for Q4 2024, compared to €0.96 million in Q4 2023. In the U.S., Q4
2024 revenue reached €1.13 million, up from €0.33 million in Q4
2023. Export activity in the rest of the world recorded €0.82
million in Q4 2024, compared to €0.36 million in the same period
last year, representing growth of +132%, mainly driven by a
recovery in orders from Europe and South America.
Revenue by Region (in € thousands -
IFRS Standards1)
2024
2023
Change %
France
1,035
956
+8%
United States
1,125
333
+237%
Rest of World
822
354
+132%
Total Revenue for the fourth
quarter
2,982
1,643
+81%
2024 Full-Year Revenue Growth of
+26%
Revenue by Activity (in € thousands
- IFRS Standards 1)
2024
2023
Change %
Revenue for the first quarter
2,223
2,208
+1%
Revenue for the second quarter
1,894
2,060
-8%
Revenue for the third quarter
2,308
1,537
+50%
Revenue for the fourth quarter
2,982
1,643
+81%
Full-Year revenue
Full-Year Spine Implants Revenue
7,034
7,067
0%
Full-Year Medical Equipment (SMTP)
Revenue
2,351
303
+676%
Full-Year Services (MADISON) Revenue
20
79
-75%
Total Full-Year Revenue
9,406
7,448
+26%
IMPLANET recorded full year revenue of €9.41 million in 2024,
compared to €7.45 million in 2023.
Spine Implants activity generated €7.03 million in 2024,
compared to €7.07 million in 2023. Meanwhile, the medical equipment
distribution activity delivered €2.35 million in 2024, representing
a growth of +676% compared to 2023.
Revenue in France grew by 17%, totaling €4.12 million. Revenue
in the United States reached €2.57 million in 2024, up +86% from
€1.38 million in 2023. Export activity in the rest of the world
also increased by 6% to €2.72 million in 2024, compared to €2.56
million in 2023.
Revenue by Region (in € thousands –
IFRS Standards1)
2024
2023
Variation %
France
4,120
3,510
+17%
United States
2,570
1,379
+86%
Rest of the World
2,716
2,560
+6%
Total Full-Year Revenue
9,406
7,448
+26%
Cash Position
As of December 31, 2024, the Company had a cash position of
€1.60 million.
As a reminder, the Company received €0.68 million related to the
sale of the MADISONTM activity, with the remaining balance of €0.17
million expected to be collected during the first half of 2025.
Additionally, on December 5, 2024, IMPLANET announced the
implementation of financing with Shanghai Pudong Development Bank
(“SPD Bank”). This financing arrangement consists of a short-term
working capital loan from SPD Bank, totaling RMB 15.2 million
(around €2 million), for a 12-month term, repayable in full at
maturity, without requiring collateral. The loan is intended for
supplier payments and other operational expenses, with repayment
guaranteed by Sanyou Medical.
Given this recent financing and cash flow projections based on
current activity assumptions and anticipated commercial
developments with Sanyou Medical for the 2024 and 2025 fiscal
years, the Company believes it will be able to meet its operational
financing needs for the next twelve months. Additionally, the
Company continues to explore various financing options to
accelerate the development of its activities and medium-term
growth, as well as the implementation of payment facilities with
the Sanyou Medical group.
Reminder of 2024
highlights
- Successful completion of the capital increase announced on
January 4, 2024, raising €5.5 million through the issuance of
83,924,897 new shares;
- Appointment of Max W. Painter as Vice President and General
Manager of IMPLANET’s US subsidiary;
- FDA clearance of the new Jazz Spinal SystemTM hybrid posterior
fixation range in the United States;
- Exclusive partnership signed for the distribution of the
ultrasonic scalpel Olea for endoscopic spine surgery in the U.S.
market.
- Financing of around €2 million with Shanghai Pudong Development
Bank.
Upcoming financial event:
- 2024 Full-Year Results: March 4, 2025, after market
close.
About IMPLANET Founded in 2007, IMPLANET is a medical
technology company that manufactures high-quality implants for
orthopedic surgery and distributing medical technology equipment.
Its activity revolves around a comprehensive innovative solution
for improving the treatment of spinal pathologies (JAZZ®)
complemented by the product range offered by Orthopaedic &
Spine Development (OSD), acquired in May 2021 (thoraco-lumbar
screws, cages and cervical plates). Implanet’s tried-and-tested
orthopedic platform is based on the traceability of its products.
Protected by four families of international patents, JAZZ® has
obtained 510(k) regulatory clearance from the Food and Drug
Administration (FDA) in the United States, the CE mark in Europe
and ANVISA approval in Brazil. In 2022, IMPLANET entered into a
commercial, technological and financial partnership with SANYOU
MEDICAL, China's second largest medical device manufacturer.
IMPLANET employs 43 staff and recorded a consolidated revenue of
€9.4 million in 2024. Based near Bordeaux in France, IMPLANET
opened a US subsidiary in Boston in 2013. IMPLANET is listed on the
Euronext Growth market in Paris. For further information, please
visit www.Implanet.com.
Disclaimer This press release contains forward-looking
statements relating to IMPLANET and its activities. IMPLANET
believes these forward-looking statements are based on reasonable
assumptions. However, no assurance can be given that the forecasts
expressed in these forward-looking statements will be realized, as
they are subject to risks, including those described in IMPLANET’s
registration document filed with the French Financial Markets
Authority (Autorité des marchés financiers – AMF) on April 16,
2018, under number D.18-0337, as well as in the annual financial
report as of December 31, 2023, both available on the Company’s
website (www.implanet-invest.com). These statements are also
subject to changes in economic conditions, financial markets, and
the markets in which IMPLANET operates. The forward-looking
statements in this press release are also subject to risks that are
unknown to IMPLANET or not currently considered material. The
occurrence of some or all of these risks could cause IMPLANET’s
actual results, financial condition, performance, or achievements
to differ significantly from those expressed in these
forward-looking statements.
This press release is for informational purposes only and does
not constitute, and should not be considered as constituting, an
offer to sell or subscribe to, or a solicitation of an offer to
purchase or subscribe to, IMPLANET’s securities in any country.
1 Unaudited figures
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250114330809/en/
IMPLANET Ludovic Lastennet, CEO David Dieumegard, CFO
Tél. : +33 (0)5 57 99 55 55 investors@Implanet.com
NewCap Investor Relations Nicolas Fossiez Tél.: +33 (0)1
44 71 94 94 Implanet@newcap.eu
NewCap Media Relations Arthur Rouillé Tél.: +33 (0)1 44
71 94 94 Implanet@newcap.eu
Implanet (EU:ALIMP)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
Implanet (EU:ALIMP)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025
